| Description | CCR4 antagonist 3-1 is a less active chemokine receptor 4 (CCR4) antagonist that inhibits [125I]TARC (thymus and activation-regulated chemokine) with an IC50 value of 1.7 μM. CCR4 antagonist 3-1 inhibits the binding of radiolabeled [125I]TARC and macrophage-derived chemokine ( MDC) to CEM cell surface and inhibits TARC-mediated CEM cell migration in vitro with an IC50 value of 6.4 μM. CCR4 antagonist 3 inhibited the binding of radiolabeled [125I]TARC and macrophage-derived chemokine (MDC) to the CCR4 receptor on the surface of CEM cells and inhibited TARC-mediated migration of CEM cells in vitro with an IC50 value of 6.4 μM. |
| In vivo | CCR4 antagonist 3-1 (compound 1) (0.5 mg/kg, i.v.; 2 mg/kg, p.o.; single dosage) exhibited a high clearance of 4.2 L/h/kg a short half-life of 0.4 h, and the oral bioavailability of 2%.[1] |
| molecular weight | 240.32 |
| Molecular formula | C14H12N2S |
| CAS | 1957-01-3 |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year |
| Solubility | DMSO: 45 mg/mL (187.25 mM), Sonication is recommended. |
| References | 1. Wang X, et al. Optimization of 2-aminothiazole derivatives as CCR4 antagonists. Bioorg Med Chem Lett. 2006 May 15;16(10):2800-3. |